Alps Advisors Inc Amgen Inc Transaction History

Alps Advisors Inc

$17.2 Billion
Q1 2025

A detailed history of Alps Advisors Inc transactions in Amgen Inc stock. As of the latest transaction made, Alps Advisors Inc holds 11,601 shares of AMGN stock, worth $3.15 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

11,601

Previous 10,449 11.02%

Holding current value

$3.15 Million

Previous $2.72 Million 32.72%

% of portfolio

0.02%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 30, 2025	BUY	$258.59 - $327.36 $297,895 - $377,118	1,152 Added 11.02%	11,601 $3.61 Million
Q4 2024 Feb 13, 2025	SELL	$258.78 - $328.31 $378,336 - $479,989	-1,462 Reduced 12.27%	10,449 $2.72 Million
Q3 2024 Nov 12, 2024	SELL	$309.38 - $337.38 $4.05 Million - $4.42 Million	-13,089 Reduced 52.36%	11,911 $3.84 Million
Q2 2024 Aug 13, 2024	BUY	$262.75 - $319.31 $450,090 - $546,978	1,713 Added 7.36%	25,000 $7.81 Million
Q1 2024 May 14, 2024	SELL	$268.87 - $324.56 $271,558 - $327,805	-1,010 Reduced 4.16%	23,287 $6.62 Million
Q4 2023 Feb 14, 2024	SELL	$255.7 - $288.46 $14,063 - $15,865	-55 Reduced 0.23%	24,297 $7 Million
Q3 2023 Nov 14, 2023	SELL	$218.65 - $271.46 $1.54 Million - $1.92 Million	-7,066 Reduced 22.49%	24,352 $6.54 Million
Q2 2023 Aug 14, 2023	SELL	$214.27 - $253.37 $178,486 - $211,057	-833 Reduced 2.58%	31,418 $6.98 Million
Q1 2023 May 10, 2023	SELL	$225.79 - $275.2 $697,691 - $850,368	-3,090 Reduced 8.74%	32,251 $7.8 Million
Q4 2022 Feb 14, 2023	SELL	$229.03 - $291.01 $23.2 Million - $29.5 Million	-101,301 Reduced 74.14%	35,341 $9.28 Million
Q3 2022 Nov 14, 2022	SELL	$224.46 - $253.15 $6.96 Million - $7.85 Million	-31,007 Reduced 18.5%	136,642 $30.8 Million
Q2 2022 Aug 11, 2022	BUY	$230.71 - $256.74 $13.9 Million - $15.5 Million	60,453 Added 56.39%	167,649 $40.8 Million
Q1 2022 May 16, 2022	SELL	$219.27 - $242.57 $661,976 - $732,318	-3,019 Reduced 2.74%	107,196 $25.9 Million
Q4 2021 Feb 09, 2022	BUY	$198.88 - $227.6 $21.9 Million - $25.1 Million	110,215 New	110,215 $24.8 Million
Q1 2021 May 07, 2021	SELL	$221.91 - $258.6 $236,556 - $275,667	-1,066 Closed	0 $0
Q4 2020 Feb 03, 2021	SELL	$216.38 - $257.67 $4,543 - $5,411	-21 Reduced 1.93%	1,066 $245,000
Q3 2020 Nov 04, 2020	BUY	$234.65 - $260.95 $26,750 - $29,748	114 Added 11.72%	1,087 $276,000
Q2 2020 Aug 05, 2020	SELL	$197.81 - $242.74 $21,363 - $26,215	-108 Reduced 9.99%	973 $229,000
Q1 2020 May 06, 2020	SELL	$182.24 - $241.7 $1.48 Million - $1.96 Million	-8,100 Reduced 88.23%	1,081 $219,000
Q4 2019 Feb 07, 2020	SELL	$189.21 - $243.2 $70,386 - $90,470	-372 Reduced 3.89%	9,181 $2.21 Million
Q3 2019 Nov 04, 2019	SELL	$174.11 - $208.62 $690,172 - $826,969	-3,964 Reduced 29.33%	9,553 $1.85 Million
Q2 2019 Aug 07, 2019	SELL	$166.7 - $195.41 $34,340 - $40,254	-206 Reduced 1.5%	13,517 $2.49 Million
Q1 2019 May 01, 2019	SELL	$180.87 - $203.88 $1.3 Million - $1.47 Million	-7,192 Reduced 34.39%	13,723 $2.61 Million
Q4 2018 Feb 04, 2019	BUY	$178.4 - $208.25 $22,656 - $26,447	127 Added 0.61%	20,915 $4.07 Million
Q3 2018 Oct 25, 2018	BUY	$185.29 - $208.89 $2.27 Million - $2.55 Million	12,226 Added 142.79%	20,788 $4.31 Million
Q2 2018 Aug 02, 2018	BUY	$166.05 - $186.51 $504,293 - $566,430	3,037 Added 54.97%	8,562 $1.58 Million
Q2 2018 Jul 25, 2018	BUY	$166.05 - $186.51 $86,179 - $96,798	519 Added 10.37%	5,525 $961,000
Q1 2018 May 01, 2018	SELL	$169.43 - $198.0 $87,934 - $102,762	-519 Reduced 9.39%	5,006 $853,000
Q4 2017 Feb 05, 2018	BUY	$168.79 - $188.59 $46,586 - $52,050	276 Added 5.26%	5,525 $961,000
Q3 2017 Nov 03, 2017	BUY	$167.29 - $191.0 $878,105 - $1 Million	5,249	5,249 $979,000

Others Institutions Holding AMGN

# of Institutions

3,306

Shares Held

429M

Call Options Held

8.06M

Put Options Held

7.7M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $145B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.

Account

Alps Advisors Inc Amgen Inc Transaction History